EUVIMEDEUVIMED entdecken
Crossref

MEVALONATE PATHWAY INHIBITION BY STATINS POTENTIATES THE ANTITUMOR ACTIVITY OF ADAGRASIB IN KRASG12C-MUTANT LUNG CANCER CELLS

A. Maestre, C. Chipón, F. Diaz, R. López-Muñoz

European Journal of Cancer · 2026-11 · 248 · 117695

DOI: 10.1016/j.ejca.2026.117695 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Cancer, 2026-11. Verfasst von A. Maestre und 3 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Zitieren

APA

Maestre, A., Chipón, C., Diaz, F., & López-Muñoz, R. (2026). MEVALONATE PATHWAY INHIBITION BY STATINS POTENTIATES THE ANTITUMOR ACTIVITY OF ADAGRASIB IN KRASG12C-MUTANT LUNG CANCER CELLS. European Journal of Cancer, 248, 117695. https://doi.org/10.1016/j.ejca.2026.117695

Vancouver

Maestre A, Chipón C, Diaz F, López-Muñoz R. MEVALONATE PATHWAY INHIBITION BY STATINS POTENTIATES THE ANTITUMOR ACTIVITY OF ADAGRASIB IN KRASG12C-MUTANT LUNG CANCER CELLS. European Journal of Cancer. 2026;248:117695. doi:10.1016/j.ejca.2026.117695

BibTeX
@article{Maestre2026,
  author = {Maestre, A. and Chipón, C. and Diaz, F. and López-Muñoz, R.},
  title = {MEVALONATE PATHWAY INHIBITION BY STATINS POTENTIATES THE ANTITUMOR ACTIVITY OF ADAGRASIB IN KRASG12C-MUTANT LUNG CANCER CELLS},
  journal = {European Journal of Cancer},
  year = {2026},
  volume = {248},
  pages = {117695},
  doi = {10.1016/j.ejca.2026.117695}
}
Kostenlos starten →